▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #352 by analyst upside · 2026-09-27
SPRO
Spero Therapeutics, Inc.
Healthcare · Market Cap $72M · P/E 8.8x
ANALYST PRICE TARGET
+306.5%
implied upside to consensus target
Current Price $1.23
Consensus Target $5.0
Bull Target $6.0
Bear Target $4.0
Analysts Covering 2
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
1
Hold
1
Sell
0
52-Week Low $1.08
52-Week High $3.08
YTD Return -47.7%
FUNDAMENTALS
Market Cap $72M
P/E Ratio (TTM) 8.8x
Forward P/E N/A
EPS (TTM) $0.14
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $47M
Profit Margin 15.7%
52-WEEK RANGE
52-Week Low $1.08
52-Week High $3.08
Current Price $1.23
Bear Target $4.0
Bull Target $6.0
● Now $1.23 ● Target $5.0
TRADING DATA
Avg Volume 1.2M
YTD Return -47.7%
Analyst Count 2
Consensus Buy
Upside to Target +306.5%
Last Updated 2026-09-27

ANALYST SUMMARY

Spero Therapeutics, Inc. (SPRO) is currently trading at $1.23 with a Wall Street consensus price target of $5.0, implying potential upside of 306.5% over the next 12 months. 2 analysts currently cover SPRO, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $6.0, while the most cautious has a target of $4.0.

SPRO operates in the Healthcare sector with a market capitalisation of $72M. The stock is down 47.7% year-to-date and is currently trading near the lower end of its 52-week range of $1.08 – $3.08.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for SPRO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. - Reiterated
Buy → Buy 2026-09-14 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-01-30 31% win rate (48 calls)
Evercore ISI Group ↓ Downgrade
Outperform → In-Line 2024-12-20 Building track record
HC Wainwright & Co. reit
Buy → Buy 2024-12-02 31% win rate (48 calls)
TD Cowen ↓ Downgrade
Buy → Hold 2024-11-18 Building track record
Cantor Fitzgerald reit
Overweight 2024-11-15 40% win rate (10 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2024-11-04 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-10-03 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
15
out of 100
Coverage depth
8/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →